IN BRIEF: Jardine Matheson completes "significant" I-MED acquisition
Jardine Matheson Holdings Ltd - Hong Kong-based holding company with interests in retail, property, hotels and motor dealerships - Completes the acquisition of Australian diagnostic imaging and teleradiology company I-MED Radiology Network. Says this "is a significant step", being "its first major investment since its transition to an investment company in 2025," and "marks the beginning of building a new earnings growth pillar". Adds that it "will closely partner with I-MED's management team to support the company's continued growth and expansion." Says I-Med is Australia and New Zealand's largest combined diagnostic imaging network, offering various medical imaging and radiology services. It operates 215 clinics and performs approximately seven million patient procedures each year.
"Jardine is proud to announce the completion of the acquisition of I-MED and to partner with the outstanding doctors and clinicians that make I-MED the leading radiology practice in Australia," comments Jardine Chief Executive Lincoln Pan. "I-MED is a trusted leader in radiology, with a long history of clinical excellence and a deep network of partners in its medical communities."
Current stock price: USD58.38
12-month change: down 6.6%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States